Prostatype Genomics AB
9 Mar - 30 Mar 2023Warrant exercise TO 2
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype.
By providing a comprehensive assessment of prostate cancer aggressiveness, Prostatype helps doctors and patients make correct treatment decisions. Over- and under-treatment of prostate cancer can be minimized, the quality of life for the patient is improved and money can be saved for healthcare.
The offer in summary
Subscription period: 9 March- 30 March 2023
Price per share: SEK 2.90
Trading with warrants: Until the 28th of March, 2023.
Payment day: 30 March 2023
Market place: First North Stockholm
Financial advicer: Sedermera Corporate Finance